A year after collaborating with Gilead, Cartography maps out its own Phase 1 with $67M Series B

Pfizer and Amgen's corporate venture arms are jumping into T cell engagers by investing in Cartography Biosciences' $67 million Series B. The Bay Area startup, which is developing bispecific and multispecific antibodies for cancer patients ...